Two COVID-19 therapeutic drugs were successfully negotiated, but Pfizer COVID-19 failed because of its high quotation.
This year, * * * through the procedures of independent declaration by enterprises, formal review and expert review, three COVID-19 therapeutic drugs, namely acyclovir tablets, nimativir tablets/ritonavir tablets (hereinafter referred to as "Paciclovir") and Qingfei Jiedu Granules, participated in the negotiation. Among them, the negotiation between afudin tablets and Qingfei Paidu Granules was successful, but the negotiation of paciclovir failed because Pfizer Investment Co., Ltd. offered too much.
The person in charge said that although paciclovir could not be included in the medical insurance catalogue through negotiation, according to the Notice on Optimizing the Medical Insurance Policies for Infected Patients in novel coronavirus after the Implementation of Type B Tube (hereinafter referred to as the Notice) recently issued by the National Medical Insurance Bureau and relevant departments, all the therapeutic drugs in novel coronavirus's infection diagnosis and treatment plan (trial tenth edition) include paciclovir, azithromycin tablets and single pull. During this period, the insured infected persons in COVID-19 can enjoy the medical insurance reimbursement policy when using these drugs.
In the national medical insurance drug list, there are more than 600 drugs for treating COVID-19's disease.
After Afuddin Tablets and Qingfei Paidu Granules were included in the national medical insurance drug list through this negotiation, there are more than 600 drugs used to treat COVID-19's symptoms such as fever and cough in the national medical insurance drug list. At the same time, in order to meet the treatment needs of infected patients in COVID-19, recently, local medical insurance departments, combined with the operation of local medical insurance funds, temporarily included a number of symptomatic treatment drugs in COVID-19 into the scope of medical insurance payment in this region. Generally speaking, there are many kinds of drugs reimbursed by medical insurance to treat COVID-19 infection.
The person in charge also said that recently, the Office of the National Medical Insurance Bureau issued the Guidelines for the Formation of Therapeutic Drugs in COVID-19 (Trial), taking full-cycle and multi-level measures to guide enterprises to make open, transparent and reasonable pricing for newly listed antiviral drugs needed for the prevention and treatment of novel coronavirus infection.
Yiling Pharmaceutical Co., Ltd.: Lianhua Qingwen Capsule (granule) was included in the novel coronavirus infection diagnosis and treatment plan (the tenth edition for trial implementation). Yiling Pharmaceutical Co., Ltd.1Announcement 65438 on the evening of October 8th. Recently, the National Health and Wellness Commission and state administration of traditional chinese medicine jointly issued the "novel coronavirus Infection Diagnosis and Treatment Program (Trial Tenth Edition)". Lianhua Qingwen Capsule, a Chinese patent medicine produced by the company, and Lianhua Qingwen Granule, a Chinese patent medicine produced by Beijing Yiling Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, are listed as light and medium-sized recommended drugs for TCM treatment in this scheme.
Will XBB cause a large-scale epidemic?
6543818, the State Council Joint Prevention and Control Mechanism held a press conference on the 10th edition of the prevention and control plan. There was a question at the meeting: With the change of exit-entry management policy, the public was worried that Omicron mutation XBB would spread in China soon. What is our professional prediction? Will XBB become the main epidemic strain in China? How to better face the possible spread risk?
Cao Chen, a researcher at the Institute of Virology, China CDC, said that in fact, XBB series offspring variants have been found in many countries, especially in the United States, and the proportion of infected patients has increased significantly. With the popularization of XBB in the world, the risk of this evolutionary branch being introduced into China and causing related cases has also increased greatly. In fact, the monitoring data show that since August 2022 1, imported XBB cases have been monitored in China, and local XBB cases 16 cases have been monitored at the same time. According to the distribution of these cases, in 2022, it was concentrated in 10 month, while in 2022, the proportion of local cases in10 month and 12 month was very low. According to this trend, XBB has no advantage in China.
He said, in fact, people in our country are vulnerable to Omicron and general. At the beginning of this epidemic, there were already many cases of local infection in many provinces, which led to a large number of national epidemics and occupied the absolute advantage of strong epidemics. In the near future, if most people are infected with these two strains, cross-protective antibodies against XBB variants will be produced in a short time, and XBB series variants will be protected in a short time, and the individual protection will last for about 6 months, so XBB will not cause a large-scale epidemic in China at this stage.
According to Cao Chen, with the discovery of new mutant strains in COVID-19, the World Health Organization has asked countries to strengthen and take some measures to prevent risks. In addition, countries should strengthen the monitoring of mutant strains in COVID-19 and issue some early warning information in time for the whole world to enjoy. China has further strengthened the monitoring of COVID-19 mutant strains, especially continued to study the global epidemic situation of XBB and the risk of its introduction into China. The epidemic situation, transmission ability, pathogenicity and immune escape ability of new variants were dynamically monitored in countries where XBB series variants are internationally prevalent. Through this monitoring, we can prevent and judge the risks of these varieties being imported into China, and we can establish some popular plans in real time.
Finally, Cao Chen reminded the public, especially those who recently entered the XBB epidemic countries, to do a good job in personal health monitoring and personal protection. If you feel unwell, you must go to COVID-19 for nucleic acid test and antigen test in time, and see a doctor if necessary. This is responsible for your own health and for others.
Zhang Wenhong's latest speech put forward two demands.
What is the future development trend of COVID-19 epidemic in China? How to save the lives of the more vulnerable groups such as the elderly? Professor Zhang Wenhong, Director of the National Center for Infectious Diseases and Director of the Infectious Diseases Department of Huashan Hospital affiliated to Fudan University, gave a keynote speech at the second Guanghua Forum held on June 7th, 65438. In his view, after entering the first wave of large-scale epidemic, China will gradually enter the stage of local epidemic and "synchronize" with the world.
In the transition period from large-scale epidemic to local epidemic, he called for the completion of drug reserves as soon as possible according to the population base of high-risk factors in various provinces and cities. "If 65,438+0,000% of patients with high-risk factors can be covered with antiviral drugs, the severe rate of high-risk factors will be effectively reduced." He also called for the full vaccination rate of the elderly over 60 to be increased to 90% as soon as possible.
"I believe that China has the ability to turn the COVID-19 epidemic into a local epidemic." Zhang Wenhong said.